NET SALES GROSS PROFIT AS A PERCENTAGE OF PHARMACEUTICAL-ONLY SALES RE SEARCH AND DEVELOPMENT, AS ADJUSTED ( a ) DILUTED EARNINGS PER SHARE FROM  CONTINUING OPERATIONS, AS ADJUSTED ( a ) In millions of dollars Growth rates in local currencies for continuing operations* 03 02 01 00 99 +23.4% +21.8% +22.6% +21.3% +18.0% $828.6 $992.1 $1,142.1 $1,385.0 $1,755.4 03 02 01 00 99 79.4% 80.1% 82.7% 85.9% 85.5% In millions of dollars P ercentage of pharmaceutical-only sales 03 02 01 00 99 18.3% 16.8% 16.5% 16.3% 16.4% $135.1 $163.7 $187.5 $228.4 $305.5 In dollars +27.0%** $1.88 (b) $1.48 (b) +22.9%*** 03 02 01 00 99 +20.3% +23.9% +26.3% +30.3% +24.0% $0.99 $1.25 $1.55 $1.92 $2.31 which consist of restructuring charge and asset write-offs of $63.5 million, duplicate operating expenses of $42.5 million and gain of $5.7 million on sale of a facility, 3) $30.2 million loss on the other than temporary impairment of equity investments, 4) $1.7 million unrealized loss on derivative instruments, 5) net gain of $1.0 million from partnering agreements, and  6) $11.7 million charge for the early extinguishment of convertible debt. The adjusted amounts in 2001 exclude the $40.0 million charge for in-process research and development related to the purchase of Allergan Specialty Therapeutics, Inc. and the after-tax effects of the following: 1) $6.2 million restructuring charge and asset write-off reversal consisting of $1.7 million restructuring charge reversal and a $4.5 million gain on sale of a  facility reducing the write-offs recorded in 1998, 2) income of $1.5 million from a partnering The adjusted amounts in 2002 exclude the after-tax effects of the following: 1) $118.7 million in litigation settlement costs, 2) net costs of $100.3 million associated with the 2002 spin-off  of the Company’s ophthalmic surgical and contact lens care businesses to Advanced Medical Optics (a) The adjusted amounts in 2003 exclude the after-tax effects of the following: 1) $179.2 million charge for in-process research and development related to the purchase of Oculex Pharmaceuticals, Inc., 2) $278.8 million charge for in-process research and development relat- ed to the purchase of Bardeen Sciences Company, LLC, 3) $0.4 million reversal of restructur- ing charge and asset write-offs, net related to the 2002 spin-off of the Company’s ophthalmic surgical and contact lens care businesses, 4) $0.3 million unrealized loss on derivative instru- ments, and 5) $0.9 million charge for the early extinguishment of convertible debt. * Growth rate in local currency is a non-GAAP financial measure. ** Growth rate is based on 2002 and 2001 adjusted  pro forma earnings per share of $1.88 and $1.48, respectively. *** Growth rate for 2003 is based on 2002 adjusted  pro forma earnings per share of $1.88.